Amy L Slogrove1, Polly Clayden, Elaine J Abrams. 1. aCentre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town bDepartment of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa cHIV i-Base, London, UK dICAP at Columbia University, Mailman School of Public Health eCollege of Physicians and Surgeons, Columbia University, New York, New York, USA.
Abstract
PURPOSE OF REVIEW: As optimized antiretroviral therapy (ART) regimens are prepared for introduction in low-income and middle-income countries (LMIC), we consider the current evidence related to dosing, efficacy and safety during pregnancy and breastfeeding of next-generation first-line and second-line ART regimens proposed for imminent introduction in the global marketplace. RECENT FINDINGS: Pregnancy pharmacokinetic considerations include potentially insufficient efavirenz exposure if dosed at 400 mg/day, the need for twice daily darunavir dosing and the paucity of data related to tenofovir alafenamide and dolutegravir dosing, safety and efficacy. Increasingly evidence suggests an association with adverse birth outcomes, particularly in women conceiving on ART, and with varying risk by drug and drug combination. Clinical trials and studies are in progress or planned that aim to determine dosing, safety and efficacy of several new antiretrovirals (ARVs). SUMMARY: Having a universal, highly potent and safe ART regimen for all individuals living with HIV in LMIC including pregnant women is clearly the most beneficial strategy to keep mothers alive and healthy and to prevent transmission of HIV to their children. It will have to be determined whether the use of this next generation of optimized ARVs will also optimize health outcomes of pregnant women and their children.
PURPOSE OF REVIEW: As optimized antiretroviral therapy (ART) regimens are prepared for introduction in low-income and middle-income countries (LMIC), we consider the current evidence related to dosing, efficacy and safety during pregnancy and breastfeeding of next-generation first-line and second-line ART regimens proposed for imminent introduction in the global marketplace. RECENT FINDINGS: Pregnancy pharmacokinetic considerations include potentially insufficientefavirenz exposure if dosed at 400 mg/day, the need for twice daily darunavir dosing and the paucity of data related to tenofovir alafenamide and dolutegravir dosing, safety and efficacy. Increasingly evidence suggests an association with adverse birth outcomes, particularly in women conceiving on ART, and with varying risk by drug and drug combination. Clinical trials and studies are in progress or planned that aim to determine dosing, safety and efficacy of several new antiretrovirals (ARVs). SUMMARY: Having a universal, highly potent and safe ART regimen for all individuals living with HIV in LMIC including pregnant women is clearly the most beneficial strategy to keep mothers alive and healthy and to prevent transmission of HIV to their children. It will have to be determined whether the use of this next generation of optimized ARVs will also optimize health outcomes of pregnant women and their children.
Authors: Angela P H Colbers; David A Hawkins; Andrea Gingelmaier; Kabamba Kabeya; Jürgen K Rockstroh; Christopher Wyen; Katharina Weizsäcker; S Tariq Sadiq; Jelena Ivanovic; Carlo Giaquinto; Graham P Taylor; José Moltó; David M Burger Journal: AIDS Date: 2013-03-13 Impact factor: 4.177
Authors: Angela Colbers; José Moltó; Jelena Ivanovic; Kabamba Kabeya; David Hawkins; Andrea Gingelmaier; Graham Taylor; Katharina Weizsäcker; S Tariq Sadiq; Marchina Van der Ende; Carlo Giaquinto; David Burger Journal: J Antimicrob Chemother Date: 2014-10-17 Impact factor: 5.790
Authors: Claire L Townsend; Laura Byrne; Mario Cortina-Borja; Claire Thorne; Annemiek de Ruiter; Hermione Lyall; Graham P Taylor; Catherine S Peckham; Pat A Tookey Journal: AIDS Date: 2014-04-24 Impact factor: 4.177
Authors: Jennifer Y Chen; Heather J Ribaudo; Sajini Souda; Natasha Parekh; Anthony Ogwu; Shahin Lockman; Kathleen Powis; Scott Dryden-Peterson; Tracy Creek; William Jimbo; Tebogo Madidimalo; Joseph Makhema; Max Essex; Roger L Shapiro Journal: J Infect Dis Date: 2012-10-12 Impact factor: 5.226
Authors: Alana T Brennan; Rachael Bonawitz; Christopher J Gill; Donald M Thea; Mary Kleinman; Johanna Useem; Lindsey Garrison; Rachel Ceccarelli; Chinenye Udokwu; Lawrence Long; Matthew P Fox Journal: AIDS Date: 2016-09-24 Impact factor: 4.177
Authors: Chrystelle O O Wedi; Shona Kirtley; Sally Hopewell; Ruth Corrigan; Stephen H Kennedy; Joris Hemelaar Journal: Lancet HIV Date: 2015-11-27 Impact factor: 12.767
Authors: Amy L Slogrove; Monika M Esser; Mark F Cotton; David P Speert; Tobias R Kollmann; Joel Singer; Julie A Bettinger Journal: Pediatr Infect Dis J Date: 2017-02 Impact factor: 2.129
Authors: Claudia S Crowell; Paige L Williams; Cenk Yildirim; Russell B Van Dyke; Renee Smith; Ellen G Chadwick; George R Seage; Alexandria Diperna; Rohan Hazra Journal: AIDS Date: 2020-07-15 Impact factor: 4.177
Authors: Ahizechukwu C Eke; Alice M Stek; Jiajia Wang; Regis Kreitchmann; David E Shapiro; Elizabeth Smith; Nahida Chakhtoura; Edmund V Capparelli; Mark Mirochnick; Brookie M Best Journal: J Acquir Immune Defic Syndr Date: 2020-04-01 Impact factor: 3.771
Authors: Dorothy C Nyemba; Emma Kalk; Hlengiwe P Madlala; Thokozile R Malaba; Amy L Slogrove; Mary-Ann Davies; Andrew Boulle; Landon Myer; Kathleen M Powis Journal: BMC Pregnancy Childbirth Date: 2021-05-04 Impact factor: 3.007